News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Who Will Win The Kidney Cancer Battle Between Bristol-Myers Squibb (BMY) And Exelixis (EXEL)?



9/15/2017 5:59:37 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
A head-to-head competition for market share in the renal cell carcinoma (RCC) market appears to be about to intensify. In one corner is Bristol-Myers Squibb (NYSE:BMY). With a market cap of over $100 billion and a history dating back to 1887, the big pharma has a lot of muscle to put behind its enormously successful cancer drug Opdivo.

Read at Motley Fool


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES